Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar companies that relate to the...more
10/19/2018
/ Antitrust Division ,
Disclosure Requirements ,
Federal Trade Commission (FTC) ,
Hatch-Waxman ,
Life Sciences ,
Manufacturers ,
Medicare Prescription Drug Improvement and Modernization Act (MMA) ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs
The Situation: The U.S. Department of Justice Antitrust Division ("DOJ") has adopted new terms in recent consent decrees that enhance DOJ's ability to enforce its settlements, most importantly by lowering the evidentiary...more
2/12/2018
/ Antitrust Division ,
Antitrust Investigations ,
Attorney's Fees ,
Burden of Proof ,
CFIUS ,
Consent Decrees ,
Corporate Counsel ,
Department of Justice (DOJ) ,
Enforcement Actions ,
Evidentiary Standards ,
Federal Trade Commission (FTC) ,
Fee-Shifting ,
Mergers